Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1634/theoncologist.2010-0256
- Scopus: eid_2-s2.0-79955012481
- PMID: 21378078
- WOS: WOS:000289558200008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The role of 18F-Fluorodeoxyglucose positron emission tomography in thyroid neoplasms
Title | The role of 18F-Fluorodeoxyglucose positron emission tomography in thyroid neoplasms |
---|---|
Authors | |
Keywords | Fluorodeoxyglucose Indeterminate cytology Positron emission tomography Thyroid carcinoma Thyroid incidentaloma |
Issue Date | 2011 |
Publisher | AlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/ |
Citation | The Oncologist, 2011, v. 16 n. 4, p. 458-466 How to Cite? |
Abstract | 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has established itself as an important imaging modality in many oncological and nononcological specialties and, as a consequence, it is increasingly being used in clinical practice. Since the first report of FDG being taken up by metastatic differentiated thyroid carcinoma (DTC) cells >20 years ago, various groups of investigators have explored the potential role of FDG-PET scanning in patients with benign and malignant thyroid neoplasms. With the increasing demand for FDG-PET scanning, clinicians are faced with the challenge of managing an increasing number of FDGPET- detected thyroid incidentalomas because their significance remains unclear. The aims of this review are to address some of these issues, specifically, the clinical significance of FDG-PET-detected thyroid incidentalomas, the ability of FDG-PET to characterize thyroid nodules, especially those with indeterminate fine needle aspiration cytology results, and the role of FDG-PET in patients with confirmed primary DTC and with suspected recurrent DTC, by reviewing the current literature. |
Persistent Identifier | http://hdl.handle.net/10722/192058 |
ISSN | 2023 Impact Factor: 4.8 2023 SCImago Journal Rankings: 1.991 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lang, BHH | - |
dc.contributor.author | Law, TT | - |
dc.date.accessioned | 2013-10-16T08:45:28Z | - |
dc.date.available | 2013-10-16T08:45:28Z | - |
dc.date.issued | 2011 | - |
dc.identifier.citation | The Oncologist, 2011, v. 16 n. 4, p. 458-466 | - |
dc.identifier.issn | 1083-7159 | - |
dc.identifier.uri | http://hdl.handle.net/10722/192058 | - |
dc.description.abstract | 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has established itself as an important imaging modality in many oncological and nononcological specialties and, as a consequence, it is increasingly being used in clinical practice. Since the first report of FDG being taken up by metastatic differentiated thyroid carcinoma (DTC) cells >20 years ago, various groups of investigators have explored the potential role of FDG-PET scanning in patients with benign and malignant thyroid neoplasms. With the increasing demand for FDG-PET scanning, clinicians are faced with the challenge of managing an increasing number of FDGPET- detected thyroid incidentalomas because their significance remains unclear. The aims of this review are to address some of these issues, specifically, the clinical significance of FDG-PET-detected thyroid incidentalomas, the ability of FDG-PET to characterize thyroid nodules, especially those with indeterminate fine needle aspiration cytology results, and the role of FDG-PET in patients with confirmed primary DTC and with suspected recurrent DTC, by reviewing the current literature. | - |
dc.language | eng | - |
dc.publisher | AlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/ | - |
dc.relation.ispartof | The Oncologist | - |
dc.subject | Fluorodeoxyglucose | - |
dc.subject | Indeterminate cytology | - |
dc.subject | Positron emission tomography | - |
dc.subject | Thyroid carcinoma | - |
dc.subject | Thyroid incidentaloma | - |
dc.title | The role of 18F-Fluorodeoxyglucose positron emission tomography in thyroid neoplasms | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lang, BHH: blang@hkucc.hku.hk | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1634/theoncologist.2010-0256 | - |
dc.identifier.pmid | 21378078 | - |
dc.identifier.pmcid | PMC3228117 | - |
dc.identifier.scopus | eid_2-s2.0-79955012481 | - |
dc.identifier.hkuros | 185527 | - |
dc.identifier.volume | 16 | - |
dc.identifier.issue | 4 | - |
dc.identifier.spage | 458 | - |
dc.identifier.epage | 466 | - |
dc.identifier.isi | WOS:000289558200008 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1083-7159 | - |